No Data
No Data
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Cuts Target Price to $13
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Lead Asset Tab-cel Undergoes FDA Priority Review
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs
Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
No Data